utilized PubMed searches to update the literature in this field, and to expand upon topics of 10 particular interest or controversy.
11
Results: We have provided an overview for the practicing urologist of the safe and economical 12 care of TaBC with regard to risk stratification, pre-and peri-operative care, subsequent 13 adjuvant treatment, surveillance, management of recurrences and long-term outcomes. Whilst 14 these recommendations are already incorporated within current guidelines, some aspects 15 deserve further discussion or have been the subject of relevant research subsequent to 16 guideline publication. 
INTRODUCTION

24
Urothelial bladder cancer (UBC) is the fifth most common cancer in Western societies, 25 accounting for 69,000 and 180,000 new cases per year in the USA and EU 1 , respectively.
26
Emerging patterns of cigarette smoking and occupational carcinogen exposure mean that the 27 incidence of UBC is rising globally 2 . However, there has been little improvement in the 28 outcome for patients with UBC since the 1980s 3, 4 , possibly reflecting complex patient pathways 29 and treatments, combined with a lack of therapeutic advances 4 .
30
As a result of the chronic clinical course of non-muscle-invasive bladder cancer (NMIBC), its 31 prevalence relative to muscle-invasive disease (MIBC), and the risks of recurrence and 32 progression that necessitate long-term cystoscopic surveillance and frequent interventions, the 33 associated cumulative costs of NMIBC are considered to be greater than those for MIBC 5, 6 . It is 34 also evident that the care for patients with NMIBC cancer varies considerably both by region 7 
35
and by physician 8 . Indeed, the latter has been shown to have more influence over the cost of 36 NMIBC care than the stage and grade of the disease itself 9 . readership. This approach is summarized in Figure 1 . 
